


In the Claims

1-31. Deleted

32. (New) A process comprising: comminuting a compound of formula I:



(I);

or a pharmaceutically acceptable salt or solvate thereof, to prepare said compound in particulate form, said particles having a mean particle size of less than about 25 microns and at least about 90% of said particles having a size of less than about 50 microns.

33. (New) The process of claim 32 wherein the compound is non-solvated crystalline 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene hydrochloride.

34. (New) The process of claim 33 wherein said particles produced have a mean particle size of between 5 and about 20 microns.

35. (New) The process of claim 34 wherein at least 90% of said particles produced have a size of less than about 35 microns.

36. (New) The process of Claim 32 further comprising mixing the product particulated compound with an excipient or carrier and compressing the mixture into tablets.

37. (New) The process of Claim 33 further comprising mixing the product particulated compound with an excipient or carrier and compressing the mixture into tablets.
38. (New) The process of Claim 34 further comprising mixing the product particulated compound with an excipient or carrier and compressing the mixture into tablets.
39. (New) The process of Claim 35 further comprising mixing the product particulated compound with an excipient or carrier and compressing the mixture into tablets.